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of HIV1-gp120 neurotoxicity
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Abstract
Background: HIV-associated neurocognitive disorders (HAND) continue to be a common morbidity associated with
chronic HIV infection. It has been shown that HIV proteins (e.g., gp120) released from infected microglial/macrophage
cells can cause neuronal damage by triggering inflammation and oxidative stress, activating aberrant kinase pathways,
and by disrupting mitochondrial function and biogenesis. Previous studies have shown that FK506, an immunophilin
ligand that modulates inflammation and mitochondrial function and inhibits calcineurin, is capable of rescuing the
neurodegenerative pathology in models of Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease. In this
context, the main objective of this study was to evaluate if FK506 could rescue the neuronal degeneration and
mitochondrial alterations in a transgenic (tg) animal model of HIV1-gp120 neurotoxicity.
Methods: GFAP-gp120 tg mice were treated with FK506 and analyzed for neuropathology, behavior, mitochondrial
markers, and calcium flux by two-photon microscopy.
Results: We found that FK506 reduced the neuronal cell loss and neuro-inflammation in the gp120 tg mice. Moreover,
while vehicle-treated gp120 tg mice displayed damaged mitochondria and increased neuro-inflammatory markers,
FK506 rescued the morphological mitochondrial alterations and neuro-inflammation while increasing levels of optic
atrophy 1 and mitofusin 1. By two-photon microscopy, calcium levels were not affected in the gp120 tg mice and no
effects of FK506 were detected. However, at a functional level, FK506 ameliorated the gp120 tg mice hyperactivity in
the open field.
Conclusions: Together, these results suggest that FK506 might be potentially neuroprotective in patients with HAND
by mitigating inflammation and mitochondrial alterations.
Keywords: FK506, gp120, HIV, Neuro-inflammation
Background
In recent years, highly effective combined antiretroviral
therapies (cART) have had remarkable success in redu-
cing the morbidity and mortality among patients with
HIV [1]; however, HIV-associated neurocognitive disorders
(HAND) continue to be a significant problem [2, 3]. HIV
enters the CNS in macrophages and T cells early in the
progression of the disease causing neuro-inflammatory and
neurodegenerative pathology [4], a condition prevalent in
the pre-cART era known as HIV encephalitis (HIVE). The
effectiveness of the cARTs has shifted HIVE from a sub-
acute condition to a low-level chronic disorder that is often
associated with mild neurodegenerative pathology and
mild HAND [5, 6].
HIV-1 proteins released from infected cells can lead to
neurodegeneration in patients with HAND through a
variety of mechanisms [7, 8]. For example, HIV-1 pro-
teins such as gp120, Tat, and Nef activate apoptotic
pathways [9], dysregulate calcium homeostasis [10, 11],
and promote excitotoxicity [12, 13] and oxidative stress
[14, 15]. In the CNS, secreted HIV-1 proteins have also
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been shown to alter autophagy pathways [16–18], aberrantly
activate kinases, and hyperphosphorylate microtubule-
associated protein tau [19, 20]. In addition, recent stud-
ies have shown that secreted HIV-1 proteins can lead
to neurodegeneration by interfering with mitochondrial
bioenergetics [21] and biogenesis [21, 22], which is
similar to alterations in mitochondrial biogenesis that
have been reported in patients with Parkinson’s disease
(PD) [23], Alzheimer’s disease (AD) [24], and Huntington’s
disease (HD) [25].
Mitochondrial biogenesis is partially regulated through
mitochondrial fusion and fission events [26]. Fission is
dependent upon the GTPase dynamin-related protein,
(DRP) 1, and appears to be crucial for regulating mito-
phagy, as well as general mitochondrial distribution allow-
ing mitochondria-organelle-contacts, Ca+ regulation, and
ATP supply to distant regions such as axonal and dendritic
synapses in neurons [27–29]. Fusion may serve as a stress
response to protect cells from apoptotic cell death [30] and
mitophagy [31]. Mitochondrial fusion is dependent on
mitofusin (MFN) 1 and 2 and optic atrophy 1 (OPA1), and
an imbalance of fusion and/or fission protein activity may
lead to dysfunction and cell death [32].
Alterations in mitochondrial fusion/fission have been
proposed to play an important role in neurodegenerative
disorders [33, 34]. We have recently reported that in the
brains of patients with HAND and in gp120 transgenic (tg)
mice levels of MFN1, OPA1, a mitochondrial dynamin-like
120 kDa protein, and DRP1 were altered [21]. These
changes are accompanied by enlarged mitochondria and al-
terations in mitochondrial bioenergetics [21]. Previous
studies have shown that FK506, an immunophilin ligand
[35, 36] that modulates mitochondrial function [37] and in-
hibits calcineurin and p38 mitogen-activated protein kinase
(MAPK) activity [38–40], is capable of rescuing the neuro-
degenerative pathology in models of AD [41], PD [42] and
HD [25]. In this context, the main objective of this study
was to evaluate if FK506 would rescue the neuronal degen-
eration and mitochondrial alterations in a transgenic animal
model of HIV-1 gp120 neurotoxicity. For this purpose,
GFAP-gp120 tg mice were treated with FK506 and analyzed
for neuropathology, calcium function, and behavior.
We found that FK506 is neuroprotective in the gp120
tg model and ameliorates mitochondrial alterations and
neuro-inflammation. These results suggest that FK506- or
FK506-like analogues might be potentially useful man-
aging the neurobehavioral alterations in patients HAND.
Methods
Generation of gp120 tg mice and treatments
For these studies, we utilized an animal model of HIV-1-
protein-mediated neurotoxicity, which expresses high
levels of gp120 under the control of the glial fibrillary
acidic protein (GFAP) promoter [43]. These mice develop
neurodegeneration accompanied by astrogliosis, micro-
gliosis, and behavioral deficits [43]. As previously described
[44], 12-month old non-tg and gp120 tg animals (total of
40 mice; n = 10 per group) received daily intraperitoneal
(IP) injections with saline (vehicle) alone or FK506 (VWR
International, Brisbane, CA) at a concentration of 5 mg/kg
for 4 weeks. The mice were sacrificed following behavioral
testing, and brains were removed for biochemical analyses
of frozen or immunocytochemical analyses of fixed brain
tissues. UCSD is an Institutional Animal Care and Use
Committee accredited institution and the Animal Subjects
Committee approved the experimental protocol (UCSD
IACUC Protocol S02221) followed in all studies according
to the Association for Assessment and Accreditation of La-
boratory Animal Care International guidelines.
Behavioral testing in the open field
The open-field locomotor test was used to determine basal
activity levels of study subjects (total move time) during a
15-min session. Spontaneous activity in an open field
(25.5 × 25.5 cm) was monitored for 15 min using an auto-
mated system (Truscan system for mice; Coulbourn In-
struments, Allentown, PA). Animals were tested within the
first 2–4 h of the dark cycle after being habituated to the
testing room for 15 min. The open field was illuminated
with an anglepoise lamp equipped with a 25-W red bulb.
Animals were tested at 12 months of age (after 4 weeks of
treatment). Time spent in-motion was automatically col-
lected 3 × 5 min time bins using the TruScan software.
Data were analyzed for both the entire 15-min session and
for each of the 5-min time blocks.
Two-photon microscopy and calcium imaging
A separate subset of non-tg and gp120 tg mice (total = 16,
n = 4 per group, 12 m/o) was anesthetized with isoflurane
(3 % initially, followed by 1–2 % during surgical proce-
dures (tracheotomy, cannulation of femoral artery, and
cortical exposure)). Surgical procedures were performed
as previously described [42, 45]. During data acquisition,
anesthesia was maintained with α-chloralose (50 mg kg−1)
and pancuronium (0.4 mg/kg). Mice were ventilated with
30 % O2 in air (~100 bpm). Expired CO2 (CI240, Colum-
bus instruments), heart rate, blood pressure (BP1, World
Precision Instruments), and body temperature (Homeo-
thermic blanket, Harvard Apparatus) were monitored
continuously. Blood gas (Rapidlab 248, Siemens) was
measured at the start of data acquisition to adjust the
respiration parameters to achieve pCO2 35–45 mmHg,
pO2 100–180 mmHg, and pH 7.35–7.45. A group of
gp120 mice (N = 4) were treated with FK506 (5 mg/kg
dissolved in 10 % ethanol 90 % saline, intra-arterial) 1 h
before imaging. The calcium indicator Oregon Green 488
BAPTA-1AM (OGB, green) was loaded by microinjection
[46], and glial marker sulforhodamine 101 (SR101, red)
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was applied topically to the brain. Images were obtained
using an Ultima two-photon laser scanning microscopy
system from Prairie Technologies, equipped with an Ultra
II femtosecond laser (Coherent) tuned to 800 nm. A single
electrical stimulus (100 μs, 1 mA) was delivered to the
contralateral whisker pad. Within each ~50 × 100 μm field
of view (FOV), neuronal cell bodies were imaged in a
frame scan mode with a target acquisition rate of 10 Hz.
Fifteen stimulus trials with interstimulus intervals (ISI) of
15 s were presented for each FOV and for each of the two
stimulus conditions.
For the extraction of time courses, masks correspond-
ing to individual neuronal bodies were segmented from
the images. For an individual neuron, calcium signal per
frame was calculated as an average of all pixels within its
cell body mask. This calculation was repeated for each
frame in the time series to generate a single-neuron time
course. The fluorescent signal (F) was expressed as the
percent change relative to the prestimulus baseline (ΔF/F).
For the calculation of averages across neurons, we recorded
single-neuron data at a cortical depth of 150 μm (layer II).
Tissue processing
In accordance with NIH guidelines for the humane treat-
ment of animals, mice were anesthetized with chloral hy-
drate and perfused transcardially with 0.9 % saline. Brains
were removed and divided sagitally. One hemibrain was
post-fixed in phosphate-buffered 4 % paraformaldehyde
(PFA) at 4 °C for 48 h and sectioned at 40 μm with a
Vibratome 2000, while the other hemibrain was snap
frozen and stored at −70 °C for protein analysis. All ex-
periments described were approved by the animal sub-
jects committee at the University of California, San
Diego (UCSD), and were performed according to NIH
recommendations for animal use.
Immunoblot analysis
The hemibrains were homogenized in Tris-buffered sa-
line (TBS) and ultracentrifuged as previously described
[21]. After determining the protein content of all sam-
ples by BCA Protein assay (Thermo Fisher Scientific),
homogenates were loaded (20 μg total protein/lane),
separated on 4–12 % Bis-Tris gels and electrophoresed
in 5 % HEPES running buffer, and blotted onto
Immobilon-P 0.45-μm membrane using NuPage trans-
fer buffer. The membranes were blocked in 5 % bovine
serum albumin (BSA) in phosphate-buffered saline-
tween 20 (PBST) for 1 h. Membranes were incubated
overnight at 4 °C with primary antibodies against cal-
cineurin (Abcam, 1:1000, rabbit polyclonal), OPA1 (BD
Biosciences, 1:1000, mouse monoclonal), MFN1 (Santa
Cruz, 1:500, rabbit polyclonal), and mitochondrial-type
heat shock protein (mtHSP)70 (BioMol, 1:500, mouse
monoclonal). Following visualization, blots were stripped
and probed with a mouse monoclonal antibody against
actin (1:2000, mab1501, Millipore), as a loading control.
All blots were then washed in PBS, .05 % tween-20, and
then incubated with secondary species-specific antibodies
(American Qualex, 1:5000 in BSA-PBST) and visualized
with enhanced chemiluminescence reagent (ECL, Perkin-
Elmer). Images were obtained, and semi-quantitative ana-
lysis was performed with the VersaDoc gel imaging system
and Quantity One software (Bio-Rad).
Analysis of neurodegeneration
Briefly, as previously described [21], blind-coded, 40-
μm-thick vibratome sections were immunolabeled with
the mouse monoclonal antibody against microtubule-as-
sociated protein-2 (MAP2, dendritic marker, 1:200, EMD
Millipore) or the antibody against synaptophysin (synaptic
marker, 1:500, Millipore). After overnight incubation, sec-
tions were treated with fluorescein isothiocyanate (FITC)-
conjugated secondary antibodies (1:75, Vector) or Tyramide
Red, (NEN Life Sciences, Boston, MA) transferred to
SuperFrost slides (Fisher Scientific), and mounted under
glass coverslips with anti-fading media (Vector Laborator-
ies, Burlingame, CA). All sections were processed under
the same standardized conditions. The immunolabeled
blind-coded sections were serially imaged with a laser
scanning confocal microscope (MRC1024, Bio-Rad) and
analyzed with the ImageJ program (NIH), as previously de-
scribed [43, 47]. For each mouse, a total of three sections
were analyzed and for each section, four fields in the frontal
cortex were examined. This brain region was selected be-
cause both patients with HAND and gp120 mice display
considerable pathology, and HIV1 gp120 concentrates in
this brain region among others (such as the striatum and
white matter). Results were expressed as percent area of the
neuropil occupied. Additional sets of sections were immu-
nostained with the mouse monoclonal antibodies against
NeuN (neuronal marker, 1:500, EMD Millipore), GFAP
(astroglial marker, 1:500, EMD Millipore), Iba-1 (microglial
marker, 1:5,000, Wako USA, Richmond, VA), or interleukin
(IL)6 (Abcam, Cambridge, MA) and developed with diami-
nobenzidine (DAB). The GFAP, Iba-1, and IL6 immuno-
stained sections were imaged with a digital Olympus
microscope (BX51) and analyzed with the Image-Pro Plus
program (Media Cybernetics). The NeuN immunostained
sections were analyzed as previously described [48] by the
dissector method with the SteroInvestigator system.
ELISA for IL6
For this assay, mouse brain homogenates (20 mg) were
prepared and ran with the mouse ELISA kit from Abcam
(ab100713). This assay utilizes an antibody specific for
mouse IL-6 coated on a 96-well plate. Standards and
samples from the mouse brain homogenates treated with
vehicle or FK506 were pipetted into the wells. The wells
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are washed, and biotinylated anti-mouse IL-6 antibody
was added. After washing, samples were treated with
HRP-conjugated streptavidin followed by washing, TMB
substrate, and stop solution. Samples were analyzed in a
plate reader for color intensity at 450 nm.
Immunocytochemical analysis of mitochondrial markers
Briefly, as previously described [21], free-floating 40-μm-
thick vibratome sections of mouse brains were washed
with Tris-buffered saline (TBS, pH 7.4), pre-treated in
3 % H2O2, and blocked with 10 % serum (Vector Labora-
tories), 3 % bovine serum albumin (Sigma), and 0.2 %
gelatin in TBS-Tween (TBS-T). Sections were incu-
bated at 4 °C overnight with primary antibodies against
calcineurin (Abcam, 1:1000, rabbit polyclonal), OPA1
(BD Biosciences, 1:1000, mouse monoclonal), MFN1
(Santa Cruz, 1:500, rabbit polyclonal), FKBP12 (Abcam,
Cambridge MA, 1:1500), or mtHSP70 (BioMol, 1:500,
mouse monoclonal). Sections were then incubated in
secondary antibody (1:75, Vector), followed by Avidin
D-horseradish peroxidase (HRP, ABC Elite, Vector), and
reacted with DAB (0.2 mg/ml) in 50-mM Tris (pH 7.4)
with 0.001 % H2O2. Control experiments consisted of in-
cubation with pre-immune rabbit serum. Immunostained
sections were imaged with a digital Olympus microscope,
and assessment of levels of optical was performed utilizing
the Image-Pro Plus program (Media Cybernetics, Silver
Spring, MD).
In addition, double immunolabeling studies were per-
formed, as previously described [21], to determine the
size and morphology of mitochondria in neuronal cells.
For this purpose, vibratome sections of mouse brains
were immunostained with antibodies against TOMM40
(Abcam, 1:1000, rabbit polyclonal; red channel) and anti-
bodies against MAP2 (Millipore, green channel). Sections
were then reacted with secondary antibodies tagged with
FITC to detect MAP2, and with the Tyramide Red amplifi-
cation system (Perkin-Elmer) to detect TOMM40, FKBP12,
and FKBP51. Sections were mounted on superfrost slides
(Fisher) and cover-slipped with media containing DAPI.
Sections were imaged with a Zeiss 63X (N.A. 1.4) objective
on an Axiovert 35 microscope (Zeiss) with an attached
MRC1024 laser scanning confocal microscope system
(BioRad, Hercules, CA). Digital images were analyzed with
the ImageJ program as previously described [21].
Statistical analysis
All the analyses were conducted on blind-coded samples.
After the results were obtained, the code was broken
and data were analyzed with the Prism (GraphPad pro-
gram, La Jolla CA). For the evaluation of statistical sig-
nificance, independent datasets were compared using
two-way ANOVA followed by the Bonferroni multiple
comparisons post hoc analysis. P values <0.05 were
considered significant. All results were expressed as
mean ± SEM. Two-photon data were analyzed in MATLAB
if they responded to stimulus in at least 13 of 15 stimulus
trials using the classic measure of area under the curve
(AUC) [42, 49]. For classical shape analysis, calcium
transients were aligned based on maximum peak slope
and normalized to the maximum peak height. Two-photon
imaging results were expressed as the mean ± SEM.
Results
FK506 ameliorates neurodegeneration and inflammation
in gp120 tg mice
We have previously shown that gp120 tg mice develop
neurodegenerative alterations between 6 and 12 months
of age [43], which is characterized by, among others,
mitochondrial alterations. For this reason, we first ana-
lyzed the effects of FK506 on the levels of neuronal
markers including NeuN, MAP2, and synaptophysin. As
expected, immunostaining with an antibody against the
neuronal marker NeuN showed that compared to the
non-tg vehicle control, the gp120 vehicle mice displayed
a 35 % neuronal loss in the fronto-temporal cortex
(Fig. 1a, b). Treatment with FK506 rescued the loss of
neurons in the gp120 tg mice (Fig. 1a, b). Immunolabeling
and confocal microscopy with an antibody against the den-
dritic marker-MAP2 (Fig. 1c) and the synaptic marker
synaptophysin (Fig. 1e) showed that compared to the non-
tg vehicle control, the gp120 vehicle-treated mice displayed
a statistically significant 40 % loss of MAP2 (Fig. 1c, d) and
30 % loss of synaptophysin (Fig. 1e, f) in the fronto-
temporal cortex. Treatment with FK506 rescued the loss of
MAP2 (Fig. 1c, d) and synaptophysin immunoreactivity
(Fig. 1e, f) in the gp120 tg mice.
Next, we analyzed the effects of FK506 on the levels of
neuro-inflammatory markers including GFAP, Iba-1, and
IL6. As shown before, immunostaining with an antibody
against the astroglial marker, GFAP, showed that com-
pared to the non-tg vehicle control mouse group, the
gp120 vehicle-treated mice displayed a 1.5-fold increase
in astrogliosis in the fronto-temporal cortex (Fig. 2a, b).
Treatment with FK506 partially reduced the astrogliosis
in the gp120 tg mice (Fig. 2a, b). Immunolabeling with
antibodies against a microglial marker, Iba-1, (Fig. 2a, c)
and a pro-inflammatory cytokine, IL6, (Fig. 2a, c) showed
that compared to the non-tg vehicle control, the gp120 tg
vehicle-treated mice displayed a onefold increase of micro-
gliosis (Fig. 2c) and 50 % increase in IL6 (Fig. 2a, d) in the
fronto-temporal cortex. Cells displaying IL6 immunoreac-
tivity were primarily astroglial based on their morphology.
Treatment with FK506 reduced the levels of microgliosis
(Fig. 2c) and IL6 (Fig. 2d) in the gp120 tg mice. To further
confirm the effects of FK506 in inflammation in the gp120
tg mice, ELISA assay to detect IL6 was performed. This
study showed an increase in IL6 in the gp120 tg mice
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compared to controls and a partial recovery following
treatment with FK506 (Fig. 2e).
Finally, we investigated by immunocytochemistry the
levels of the FK506-binding proteins (FKBP) 12 and
FKBP51. FKBP12 is a 12-kDa, ubiquitous abundant pro-
tein that binds tightly to intracellular calcium release
channels and regulates inflammatory responses [50]. The
larger members, FKBP51 and FKBP52, interact with
Hsp90 and exhibit chaperone activity that is shown to
regulate signaling in the CNS and the immune system
[24]. FKBP12 immunoreactivity was observed in pyram-
idal neurons and in the neuropil (Fig. 3a), compared to
vehicle, treatment with FK506 increased the levels of
FKBP12 immunoreactivity in the non-tg and gp120 tg
groups (Fig. 3a, b). Likewise, FKBP51 immunolabeling
was observed in the cell body of pyramidal neurons
(Fig. 3c); compared to the vehicle-treated group, FK506
increased the levels of FKBP51 immunostaining in the
non-tg and gp120 tg groups (Fig. 3c, d). To confirm that
FKBP12 and FKBP51 immunolabeling was in pyramidal
neurons, double-labeling studies with MAP2 were per-
formed in non-tg vehicle-treated mice (Fig. 3e). Taken
together, these results suggest that FK506 engages
FKBP that might modulate inflammatory responses in
the CNS.
FK506 rescues the structural mitochondrial alterations in
gp120 tg mice
Given that FK506 was neuroprotective in the gp120 tg
mice, gp120 mice display mitochondrial alterations [21],
and previous studies have shown that calcineurin, a tar-
get of FK506, modulates mitochondria; we next analyzed
levels of mitochondrial markers in FK506-treated ani-
mals using microscopy and biochemical assays. Consist-
ent with previous observations [21], immunolabeling
and confocal microscopy with an antibody against the
mitochondrial marker TOMM40 showed that compared
to the non-tg vehicle control, the gp120 vehicle-treated
mice displayed a 45 % increase in the size of the mito-
chondria (Fig. 4a arrowheads, b), which appeared irregu-
lar and appeared abnormally fused in MAP2-positive
neurons in the fronto-temporal cortex (Fig. 2a, detail).
In contrast, the mitochondria of gp120 tg mice treated
with FK506 were comparable to the non-tg controls
(Fig. 4a, b). Analysis of levels of MAP2-immunoreactivity
was presented in Fig. 1.
Fig. 1 Effects of FK506 on markers of neurodegeneration in gp120 tg mice. Non-tg and gp120 tg mice were treated with vehicle or FK506 for
4 weeks, and immunostained serial vibratome sections were analyzed by digital bright-field microscopy and confocal microscopy. Representative
images are shown from the frontal cortex. a Representative bright-field microscopic images and b computer-aided ImageJ analysis of sections
incubated with an antibody against the neuronal marker NeuN showing decreased immunoreactivity in the neocortex in vehicle-treated gp120
tg mice. In vehicle-treated gp120 tg mice, there was a significant decrease (*p < 0.05, by one-way ANOVA post hoc Dunnett’s), while FK506 t
reatment ameliorated the neuronal alterations compared to vehicle-treated gp120 tg mice (#p < 0.05, by one-way ANOVA post hoc Tukey-Kramer).
c Immunocytochemical analysis and confocal microscopy of sections labeled with an antibody against the dendritic marker MAP2 (FITC channel).
d Computer-aided ImageJ analysis of the % area of the neuropil that is MAP2 immunostained. In vehicle-treated gp120 tg mice, there was a significant
decrease in MAP2 immunoreactivity. e Immunofluorescent microscopy and f image analysis of the synaptic marker synaptophysin revealed a
statistically significant synaptic loss in vehicle-treated gp120 mice compared to vehicle-treated non-tg mice, and treatment with FK506 rescued the
synaptic loss in gp120 mice. Scale bar = 20 μm. *p value <0.05 by one-way ANOVA and Dunnett’s post hoc analysis compared to vehicle; N = 10;
age = 12 months of age
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Immunocytochemistry and bright-field microscopy with
an antibody against calcineurin showed that calcineurin-
immunoreactivity was localized to the neuronal cell bodies
and neuritic process in the non-tg and gp120 tg mice
(Fig. 5a, b), and no significant differences were detected be-
tween non-tg vehicle control and the gp120 tg mice treated
with vehicle or FK506 (Fig. 5a, b). Antibodies against mito-
chondrial proteins such as OPA1, MFN1, and mtHSP70
displayed a granular pattern (arrowheads) of immunostain-
ing in neuronal cells in the neocortex (Fig. 5a). Compared
to the non-tg vehicle control, the gp120 tg vehicle-treated
mice displayed a statistically significant 40 % loss of the
mitochondrial protein OPA1 (Fig. 5a, c) in the fronto-
temporal cortex. Treatment with FK506 rescued the loss of
OPA1 in the gp120 tg mice (Fig. 5a, c). Levels of MFN1
showed non-significant decrease in FK506-treated non-tg
mice and a trend toward an increase in vehicle-treated
gp120 tg mice compared to non-tg mice (Fig. 5a, d); treat-
ment with FK506 led to a statistically significant increase
in levels of MFN1 in gp120 tg mice (Fig. 5a, d). Levels of
mtHSP70 were comparable among the four groups, and
no effects of FK506 were detected (Fig. 5a, e).
In order to verify these results by an independent
approach, immunoblot analysis was performed with
membrane fractions from each of the four genotype/
treatment groups. Calcineurin was detected as a single
band at approximately 59 kDa (Fig. 6a). Levels of calcine-
urin were comparable among the four groups, and no ef-
fects of FK506 were detected (Fig. 6a, b). OPA1 was
detected as a doublet at approximately 90 kDa. Compared
to the non-tg vehicle control, the gp120 tg vehicle mice
displayed a non-significant 20 % decrease in OPA1 (Fig. 6a,
c), and treatment with FK506 significantly increased the
OPA1 levels in the gp120 tg mice (Fig. 6a, c). MFN1 was
detected as a doublet at approximately 70–80 kDa (Fig. 6a).
Levels of MFN1 showed a trend toward an increase in
vehicle-treated gp120 tg mice compared to non-tg mice
(Fig. 6a, d), and treatment with FK506 significantly in-
creased levels of MFN1 in gp120 tg mice (Fig. 6a, d).
mtHSP70 was detected as a single band at approximately
72 kDa (Fig. 6a). Levels of mtHSP70 were comparable
among the four groups of mice (Fig. 6a, e).
FK506 ameliorates the hyperactivity in gp120 tg mice but
no effects of calcium imaging by two-photon microscopy
Next, we investigated the functional effects of FK506 in
the gp120 tg mice both in the open field and by calcium
live imaging. As previously described [51], we found that
Fig. 2 Immunohistochemical and ELISA analysis of the effects of FK506 on markers of neuro-inflammation in gp120 tg mice. Non-tg and gp120
tg mice were treated with vehicle or FK506 for 4 weeks, and serial vibratome sections were treated by immunohistochemistry (IHC) and analyzed
by digital bright-field microscopy. Representative images are shown from the fronto-temporal cortex. a Photomicrographs of GFAP-, Iba-1-, and
IL6-positive astroglial cells in the fronto-temporal cortex of control and gp120 tg mice. b Image analysis of the sections showing increase GFAP in
gp120 mice vehicle-treated mice, and treatment of gp120 mice with FK506 significantly decreased astrogliosis compared to vehicle-treated gp120 mice.
c Image analysis of microglial marker Iba-1 showed that vehicle-treated gp120 mice had a statistically significant fold-increase in microgliosis compared to
vehicle-treated non-tg mice. Treatment with FK506 significantly reduced the microgliosis in gp120 mice compared to vehicle-treated gp120 mice. d Image
analysis of cytokine IL6 indicated a statistically significant increase in IL6-immunoreactivity in vehicle-treated gp120 mice compared to non-tg mice. FK506
significantly reduced IL6 levels in gp120 mice compared to vehicle-treated gp120 mice. e ELISA assay analysis of levels of IL6 in non-tg and gp120 tg mice
treated with vehicle and FK506 showed a statistically significant increase in vehicle-treated gp120 mice compared to non-tg vehicle-treated mice which
FK506 treatment significantly reduced. Scale bar = 25 μm. *p value <0.05 by one-way ANOVA and post hoc Dunnett’s compared to vehicle; #p value <0.05
by one-way ANOVA and Tukey-Krammer post hoc test compared to vehicle-treated gp120 mice; N= 10; age = 12 months of age
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compared to non-tg vehicle, the gp120 tg vehicle-treated
mice were hyperactive in the open field as reflected by
the increase beam breaks (Fig. 7a) and distance traveled
(Fig. 7b); treatment with FK506 recovered the levels of
activity back to the baseline (Fig. 7a, b). However, levels
of thigmotaxis (time expended in borders of the cage vs.
the center) and rearing were comparable among the four
groups of mice, and no effects of FK506 were detected
(Fig. 7c, d).
Since we have previously shown that in various models
of neurodegeneration the mitochondrial calcium buffer-
ing capacity is abnormal and this is recovered by FK506
[42], next we investigated if the gp120 tg mice displayed
similar deficits and if FK506 will rescue the defects. For
this purpose, the barrel cortices of non-tg and gp120 tg
mice were analyzed using the 1-Hz stimulus paradigm
and a depth of 150 μm (Fig. 8). Neurons, labeled with
calcium indicator Oregon green 488 BAPTA (OGB1),
appeared in green (Fig. 8a). Astrocytes, labeled with both
OGB and SR101, appeared in yellow (Fig. 7a), or as white
(Fig. 8b). The masks for the region of interests (ROIs) for
neurons and astrocytes (Fig. 8c) were used for the initial
processing of individual calcium traces (Fig. 8d). Calcium
transients were normalized for peak shape in order to
evaluate the peak shapes using AUC. Under the 1-Hz
stimulus paradigm and at a depth of 150 μm, the calcium
transients from the gp120 tg mice with and without
FK506 treatment had geometric shapes indistinguishable
from the non-tg mice (Fig. 8e). Similarly, the AUCs
were indistinguishable from non-tg mice (Fig. 8f). Taken
together, these results suggest that independent of calcium
currents, FK506 rescues the neurodegenerative, mito-
chondrial pathology, and hyperactivity behavior in the
gp120 tg mice.
Discussion
Immunophilin ligands such as cyclosporine A, rapamycin,
and FK506 are well-known immunosuppressive drugs
Fig. 3 Immunocytochemical and confocal analysis of the effects on FK506-binding proteins in gp120 tg mice. Non-tg and gp120 tg mice were
treated with vehicle or FK506 for 4 weeks and immunostained with antibodies against FKBP12 and 51. Representative images are shown from the
fronto-temporal cortex. a Photomicrographs and b image analysis of FKBP12-positive neurons showing that FK506 treatment increased FKBP12 in
the non-tg and gp120 tg mice. c Photomicrographs and d image analysis of FKBP51-positive neurons showing that FK506 treatment increased
FKBP51 in the non-tg and gp120 tg mice. e Confocal images showing colocalization of FKBP12 (red, upper panel) and FKBP51 (red, lower panel),
respectively, with dendritic marker MAP2 (green). Scale bar in a = 10 μm. Scale bar in e = 10 μm. *p value <0.05 by one-way ANOVA and post hoc
Dunnett’s compared to vehicle; #p value <0.05 by one-way ANOVA and Tukey-Krammer post hoc test compared to vehicle-treated gp120 mice;
N = 10; age = 12 months of age
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Fig. 4 Double immunocytochemistry and analysis of the effects of FK506 on mitochondria morphology in neuronal cells. Non-tg and gp120 tg
mice were treated with vehicle or FK506 for 4 weeks and vibratome sections double-immunostained with MAP2 (dendritic marker) and TOMM40
(mitochondrial marker) analyzed by digital florescent microscopy. Representative images are shown from the fronto-temporal cortex. a Double
immunofluorescent microscopy of MAP 2 (green) and TOMM40 (red) was performed to determine size and morphology of mitochondria in neuronal
cells. White arrowheads indicate TOMM40-positive reference mitochondria. The detailed images are higher magnification of the inset box. b Image
analysis of mitochondrial marker TOMM40 (white arrows) indicated a statistically significant increase in mitochondrial size in vehicle-treated gp120 mice
compared to vehicle-treated non-tg mice. FK506-treated gp120 mice had a statistically significant reduction in TOMM40 mitochondrial marker
(white arrows) indicating a reduction in mitochondrial size compared to vehicle-treated gp120 mice. Scale bar = 10 μm; detailed scale bar= 1 μm.
*p value <0.05 by one-way ANOVA and post hoc Dunnett’s compared to vehicle; N = 10; age = 12 months of age
Fig. 5 Immunocytochemical analysis of the effects of FK506 on the FK506-binding protein, calcineurin, and markers of mitochondrial fusion in
non-tg and gp120 tg mice. Non-tg and gp120 tg mice were treated with vehicle or FK506 for 4 weeks, and serial vibratome sections were
immunostained and analyzed by digital bright-field microscopy. Representative images are shown from the frontal cortex. Calcineurin is an
FK506-binding protein, and OPA1 and MFN1 are GTPases that are required for mitochondrial fusion. Black arrowheads indicate the granular
staining pattern. a Representative bright-field microscopic images and b computer-aided ImageJ analysis of sections incubated with antibodies against
calcineurin, which was unaffected by mouse type or treatment, while c OPA1 was significantly decreased in vehicle-treated gp120 tg mice compared
to vehicle-treated non-tg mice. Treatment of gp120 mice with FK506 rescued the loss of OPA1. d Levels of MFN1 were significantly increased
in FK506-treated gp120 mice compared to vehicle-treated non-tg mice. e mtHSP70 was included as a control protein and was unaffected by
treatment or mouse type. Scale bar = 20 μm. *p < 0.05, by one-way ANOVA post hoc Dunnett’s; #p < 0.05, by one-way ANOVA post hoc Tukey-Kramer.
N = 10; age = 12 months of age
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widely used in transplantation medicine. These compounds
have also been utilized or investigated as treatments for
various types of cancer, hepatitis C, and as neuroprotective
agents [52]. We have recently shown that FK506 rescues
the mitochondrial calcium buffering defects in PD α-
synuclein models [42], and for the present study, we in-
vestigated the neuroprotective properties of FK506 in a
model of HIV-1 gp120-mediated neurotoxicity. Here,
we show that FK506 reduced the neuronal damage and
neuro-inflammation in the gp120 tg mice. Moreover,
while vehicle-treated gp120 tg mice displayed damaged
mitochondria and increased markers of neuroinflamma-
tion, FK506 rescued the morphological mitochondrial
alterations, decreased levels of GFAP and Iba1, and in-
creased FKBP12 and 51.
These results are consistent with previous studies
showing that FK506 is neuroprotective in models of
stroke [53], spinal cord injury [54], and neurodegenera-
tion [41], including models of PD [55, 56], AD [24], and
HD [25]. FK506 has also been found to be protective in
a model of antiretroviral toxic neuropathy [57]. Several
mechanisms of action have been proposed to explain the
neuroprotective effects of FK506 [35]. For example, it
has been shown that FK506 effects might be mediated
by a large family of co-chaperone proteins called the
FK506-binding proteins (FKBPs) [35]. Recently, changes
in the levels of FKBP51 and FKBP52 have been correlated
with short-term recognition memory impairment in aged
mice [58]. Since all FKBPs including FKBP51 and FKBP52
contain a domain with prolyl cis/trans isomerase (PPIase)
Fig. 6 Immunoblot analysis of the effects of FK506 on the FK506-binding protein, calcineurin, and markers of mitochondrial fusion in non-tg and
gp120 tg mice. Non-tg and gp120 tg mice were treated with vehicle or FK506 for 4 weeks and were analyzed by immunoblot. a Representative
Western blots are shown from the membrane fraction of whole brain lysate that was immunoreacted with antibodies against calcineurin, an
FK506-binding protein, OPA1 and MFN1, GTPases that are required for mitochondrial fusion, and mtHSP70, a mitochondrial housekeeping control
protein. b Computer-aided analysis of sections incubated with an antibody against calcineurin, which was unaffected by mouse type or treatment.
c OPA1 was detected as a doublet which was non-significantly decreased in vehicle-treated gp120 tg mice compared to vehicle-treated non-tg mice.
Treatment of gp120 mice with FK506 led to a statistically significant increase in OPA1 compared to vehicle-treated non-tg mice. d Levels of MFN1 were
detected as a double tat approximately 70–80 kDa and were significantly increased in FK506-treated gp120 mice compared to vehicle-treated non-tg
mice. e mtHSP70 was detected as a single band, was included as a control protein, and was unaffected by treatment or mouse type. *p < 0.05, by
one-way ANOVA post hoc Dunnett’s; #p < 0.05, by one-way ANOVA post hoc Tukey-Kramer. N = 10; age = 12 months of age
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activity [24], when FK506 binds to this domain, it inhibits
their PPIase activity and prevents mitochondria from cal-
cium overload while also modulating immune suppression
by blocking calcineurin. Along these lines, in the present
study, we found that FK506 increased levels of FKBP12
and 51 in the non-tg and gp120 tg mice, proteins involved
in the anti-inflammatory and neuro-modulatory effects of
FK506.
Another neuroprotective mechanism that has been
proposed for FK506 involves the FKBPs interact with
Hsp90 and exhibit chaperone activity that might be re-
sponsible for the neuroprotective effects [24]. Protein
dephosphorylation by calcineurin plays an important
role in neuronal signaling relevant to the regulation of
calcium channels, glutamate release, and synaptic plasti-
city. In vitro, FK506 protects cortical neurons from
NMDA-induced death and promotes phosphorylation of
nitric oxide synthase thereby inhibiting its activity and
nitric oxide synthesis. FK506 also inhibits p38 MAPK-
mediated inflammation [39, 40]. However, it is less clear
if this mechanism is as relevant in vivo, and the potential
anti-inflammatory effects of FK506 have been proposed
as a potential neuroprotection mechanism [59]. For the
present study, we showed that in addition to protecting
the neuronal architecture from gp120 neurotoxicity,
FK506 reduced inflammation as assessed by immuno-
staining with antibodies against GFAP, Iba1, and IL6.
Our findings are in agreement with previous studies,
which have shown that FK506 targets astrocytes and
microglia and modulates neuro-inflammation ischemia
and neurodegeneration [53]. FK506 reduced IL-1β, IL-6,
and TNF-α expression in models of stroke and inhibited
the lipopolysaccharide-induced activation and cytokine
expression in microglia in vitro [53].
Another FK506-induced mechanism involves the acti-
vation of autophagolysosomal pathways that enhance
the clearance of aggregated misfolded proteins such as
PrPsc [60]. In this study, FK506 increased the levels of
autophagy-related molecules such as LC3-II, ATG12-
ATG5, and ATG7. In the gp120 tg mice, we have previously
shown alterations in autophagy [61]; however, the effects of
FK506 in this pathway in gp120 tg mice are unclear; future
studies will address this question. Furthermore, recent
studies have suggested that FK506 acts at the level of
the mitochondria by modulating abnormal cytosolic
and mitochondrial Ca2+ dynamics [37]. FK506 has also
been shown to decrease the ionophore-induced rise in
[Ca2+]i in both neurons and astrocytes [62]. Along
these lines, it has been shown that FK506 reduces
mitochondrial-dependent apoptotic cell death induced
by 3-nitropropionic acid in neuronal cultures [63]. Likewise,
we have recently reported that FK506 rescues the alter-
ations in the mitochondrial-dependent calcium buffering
capacity in amyloid precursor protein, α-synuclein, and
microtubule-associated protein tau tg mice [42]. For the
present study, we found that neuroprotective effects of
FK506 were associated with the amelioration of the mito-
chondrial morphological and biochemical alterations in the
gp120 tg mice. Moreover, we found improvements in the
hyperactivity in the gp120 tg mice. However, while previous
Fig. 7 Effects of FK506 treatment on behavior in non-tg and gp120 tg mice. Four behaviors were evaluated in the open field test: total activity,
total distance, thigmotaxis, and rearing. a Vehicle-treated gp120 tg mice were hyperactive compared to non-tg mice, and FK506 treatment significantly
reduced the activity levels compared to vehicle-treated gp120 tg mice. b Vehicle-treated gp120 tg mice covered a significantly greater total distance
compared to vehicle-treated non-tg mice. c Thigmotaxis and d rearing were not significantly different between mouse type or treatment group.
Scale bar= 10 μm. *p < 0.05, by one-way ANOVA post hoc Dunnett’s. N = 10; age = 12 months of age
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in vitro studies indicate that gp120 triggers calcium alter-
ations [14], by two-photon microscopy, there were no ap-
parent abnormalities in calcium transients in gp120 tg
mice. The current findings are, however, consistent with
previous studies [21], in which we found that in HAND
and gp120 tg mouse model levels of MFN1 are increased.
MFN1 is a dynamin-related protein of the outer mitochon-
drial membrane that functions in concert with OPA1 to
regulate mitochondrial fusion [64], a function that cells
may utilize to dilute the contents of damaged mitochondria
in response to stress and prevent apoptosis [65]. In the
current study, FK506 further enhanced MFN1 expression.
This suggests that the beneficial effects of FK506 in this
model of HIV1 neurotoxicity might be independent of
calcium and be more closely related to the regulation
of neuroinflammation and mitochondria. Future ana-
lyses will focus more closely on the anti-inflammatory
and autophagy-modulating mechanisms of FK506. As
in the general fight against HIV infection, and in this
study, therapies that target multiple cellular processes
may be the most effective at treating HIV-induced
neurodegeneration.
Conclusions
We found that FK506 is neuroprotective in the gp120 tg
model most likely by reducing inflammation and improving
mitochondrial morphology. Together, these results suggest
that FK506 might be potentially useful in the therapeutic
management of patients with HAND.
Fig. 8 Calcium dynamics by live imaging in the barrel cortex neurons in gp120 tg mice treated with FK506. a Composite two-photon image of
the calcium indicator dye, OGB (green), and astrocyte marker, SR101 (yellow-orange). Representative two-photon images indicating the SR101-
positive structures in each mouse type. Regions of interest for each image were extracted; neurons are indicated in green and astrocytes are in
red. b The time course for the calcium signal was extracted based on regions of interest identified in the previous panel for 1 Hz. The arrows indi-
cate the onset of the stimulus. c Visual representation of average calcium peak shapes for non-tg, GP120, and GP120 mice treated with FK506
mice using 1Hz stimulus frequency at a depth of 150 μm. d There was no significant difference between normalized calcium traces from barrel
cortex neurons that were quantified using area under the curve (AUC). Scale bar for photomicrographs is 10 μm
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